Arecor Therapeutics (AREC)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

140.00p
   
  • Change Today:
      2.50p
  • 52 Week High: 270.00
  • 52 Week Low: 132.50
  • Currency: UK Pounds
  • Shares Issued: 30.63m
  • Volume: 23,983
  • Market Cap: £42.88m

Arecor granted first US patent for insulin formulations

By Josh White

Date: Wednesday 23 Mar 2022

LONDON (ShareCast) - (Sharecast News) - Biopharmaceutical company Arecor Therapeutics announced on Wednesday that the United States Patent and Trademark Office has granted a patent protecting novel formulations of its proprietary insulin products, 'AT247' and 'AT278'.
The AIM-traded firm said it was investing in building a "strong" patent portfolio to protect the 'Arestat' technology platform and its proprietary pipeline products.

Its intellectual property portfolio currently consisted of 36 patent families, including more than 50 granted patents in Europe, the US and in other key territories.

As part of its strategy, Arecor said it had "robust" intellectual property directed to the novel insulin compositions, protecting different aspects of AT247 and AT278 formulations, as well as their specific properties and methods of use.

The company said its strategy was to generate a "fortress" of both narrow and broad interrelated intellectual property rights covering the features of the products.

US11278624 was the first granted US patent within its insulin intellectual property strategy.

"Arecor's novel insulin products, based on a combination of existing insulin analogues and our highly innovative formulation science, have potential to improve convenience, compliance and enable more effective management of blood glucose for people living with type 1 and type 2 diabetes," said chief scientific officer Dr Jan Jezek.

"As the clinical validation of the superiority of these products compared to current gold standard prandial insulins continues, we are also advancing the intellectual property protection for these products.

"This recently granted US patent, the first within the group's comprehensive insulin IP strategy, is a significant milestone, and we will continue to strengthen our IP portfolio with additional patent applications already in progress."

At 1116 GMT, shares in Aercor Therapeutics were up 8.17% at 397p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

AREC Market Data

Currency UK Pounds
Share Price 140.00p
Change Today 2.50p
% Change 1.82 %
52 Week High 270.00
52 Week Low 132.50
Volume 23,983
Shares Issued 30.63m
Market Cap £42.88m

AREC Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
44.58% below the market average44.58% below the market average44.58% below the market average44.58% below the market average44.58% below the market average
25.93% above the sector average25.93% above the sector average25.93% above the sector average25.93% above the sector average25.93% above the sector average
Price Trend
73.14% below the market average73.14% below the market average73.14% below the market average73.14% below the market average73.14% below the market average
15.79% below the sector average15.79% below the sector average15.79% below the sector average15.79% below the sector average15.79% below the sector average
Income Not Available
Growth
32.96% above the market average32.96% above the market average32.96% above the market average32.96% above the market average32.96% above the market average
56.76% above the sector average56.76% above the sector average56.76% above the sector average56.76% above the sector average56.76% above the sector average

AREC Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
16:25 228 @ 135.00p
16:14 1,800 @ 135.00p
15:17 225 @ 139.00p
14:24 230 @ 139.00p
11:19 10,000 @ 137.00p

AREC Key Personnel

CEO Sarah Jennifer Howell
CFO Susan Lowther

Top of Page